Genzyme obtains license for cancer diagnostic
January 15, 2008 11:53 AM
E-mail|
|Comments
()|
Text size
–
+
Cambridge biotechnology company Genzyme Corp. announced today a license agreement for exclusive rights to a lung-cancer diagnostic.
The agreement is with Moffitt Cancer Center of Florida.
Under the agreement, Genzyme said it will obtain exclusive diagnostic testing rights to the discovery of the relationship of two proteins to patient response to non-small cell lung cancer treatment.
(By Chris Reidy, Globe staff)
Comment
Permalink
E-mail
